Creating sustainability and longevity for biosimilars


Connect With an Expert

Sean McGowan, Sr. Director, Biosimilars at amerisourcebergen
Contact Sean

We advance access with integrated commercialization services for all biosimilars

“The recent pandemic state produced a spotlight on the need to drive savings within the U. S. pharmaceutical market – biosimilars are one of many solutions to reducing downstream cost.  The importance of staying diligent and continuing to drive choice, access and savings is a top priority at AmerisourceBergen.”

-Michelle Jesse, Director, Biosimilar Commercialization 
Our relationships span:
health systems
100%
of u.s. hospitals
oncology
60%
of U.S. community oncology market
nephrology
90%
of U.S. renal market
opHthamology
4,200
provider sites
rheumatology
2,100
provider sites

Resources & Education

Read the FDA's guidance on biosimilars and get answers to patients' frequently asked questions.

 

"The right conditions exist in the U.S. for biosimilar commercialization success. Competition has proven to bring prices down – look at the generics market over the last 30 years – but now we need to create a supportive system."

STEVE COLLIS, CHAIRMAN, PRESIDENT AND CEO, AMERISOURCEBERGEN 

Read more